NCT00226980View on ClinicalTrials.gov

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2006

Conditions

Kidney Neoplasms

Interventions

DRUG

Thalidomide

DRUG

Capecitabine

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Stanford University

OTHER

NCT00226980 - A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter